InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.060 -0.014 (-18.92%)+
Announcement
Release
13 May 2026 9:19AM
Price at Release
$0.074
Full Release
download
Summary
Neurizon Therapeutics Limited has received ethics approval from the Bellberry Human Research Ethics Committee (HREC) to proceed with a Phase 1 study of its NUZ-001 oral liquid formulation. This study is a crucial step in developing the NUZ-001 treatment for amyotrophic lateral sclerosis (ALS), focusing on improving treatment accessibility and administration flexibility, particularly as the disease progresses and swallowing difficulties increase. The study will enroll 32 healthy volunteers in a randomized, four-arm trial in Australia to evaluate both oral liquid and tablet formulations under fed and fasted conditions, aiming to collect pharmacokinetic, safety, tolerability, and exploratory biomarker data. The study results will support the clinical, regulatory, and commercial development of NUZ-001, as part of Neurizon's broader development program, which includes participation in the Phase 2/3 HEALEY ALS Platform Trial in the United States.
Key Points
  • Ethics approval received for NUZ-001 Phase 1 oral liquid study.
  • Study supports development for treatment of ALS.
  • 32 healthy volunteers to participate in Australia.
  • Focus on improving treatment accessibility for ALS patients.
  • Data collection includes pharmacokinetic, safety, and tolerability.
  • Part of broader NUZ-001 development and ALS program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.